TheDinarian
News • Business • Investing & Finance
How Rockefeller Monopolized Medicine and Created BIG PHARMA
Please read and share, let the truth be known worldwide...
October 13, 2023
post photo preview

Born in 1839, John D. Rockefeller would go on to become one of the great robber barons and industrialist tycoons of American history. By the turn of the 20th century, Rockefeller controlled 90% of the oil refineries in the US through his company Standard Oil, becoming in the process America’s first billionaire.

Of course, in 1911, Standard Oil was ruled by the US Supreme Court to be an illegal monopoly in violation of antitrust laws and forced to break up. Like his father, John D. Rockefeller had built his success on illegality, cons, and scams.

Still, this was not enough for Rockefeller. He wanted more.

 

How Rockefeller Targeted Medicine

At the time, chemicals made from oil, known as ‘petrochemicals,’ were being discovered and developed in the US. This included the discovery that pharmaceutical drugs could be made from oil, which Rockefeller saw as an opportunity to expand his empire. The key was that petrochemicals, unlike natural health remedies, could be patented, presenting an enormous opportunity for Rockefeller profits.

There was only one problem – at the time, natural, herbal, and traditional medicines were very popular in the US. Something like half of the doctors and medical colleges in the country were using holistic medicine, natural remedies, and knowledge taken from Indigenous Native Americans. Rockefeller needed a way to eliminate the competition, to create a monopoly in medicine as he had done with oil.

And so, he went to his good friend Andrew Carnegie, another robber baron who had gotten rich through his monopoly of the steel industry and, incidentally, one of the country’s leading eugenicists. Together, the two men hatched a plan to take over American medicine.


maxresdefault.jpg

 

The Creation of Big Pharma

From the cover of the Carnegie Foundation, they would send a man named Abraham Flexner around the country to report on its medical colleges and hospitals. After visiting all 155 medical schools existing at that time in the US and Canada, he completed the seminal Flexner Report in 1910.

Following the directions of his employers, Flexner called in his report for a total restructuring of the American medical system, most specifically, for the pushing aside of natural and traditional remedies in favor of Rockefeller pharmaceuticals. The report even specifically mentioned the eradication of “dissidents,” appropriately, since this is exactly what happened.

Almost immediately after the report was issued, medical schools teaching things like naturopathy, homeopathy, electromagnetic field therapy, and so on, were told to drop these things or close. More than half of all medical colleges in the country did close, and many non-compliant doctors were demonized and even jailed.

But Rockefeller and Carnegie went further, offering huge grants to medical schools and hospitals so long as they only taught and practiced Rockefeller medicine, and allowed Rockefeller agents on their boards of directors to ensure compliance.

It was the carrot and the stick – those who agreed got funded with big money, those who didn’t were crushed.

In this way, all medical colleges in the country were streamlined and homogenized, with doctors all learning the same thing – how to use and prescribe Rockefeller’s patented drugs.

But, like any good monopolist, Rockefeller went further in seeking to consolidate his control. He took over the AMA and emboldened it as the gatekeeper of scientific thought and witch hunter of alternative medical practices. He took control of the FDA in order to control the approval process for new drugs. He even founded the American Cancer Society in 1913. Within a few short years, Rockefeller was in total control of the American medical system in both thought and action.

The result of this takeover, the product of this monopolist son of a conman and his eugenicist partner, would become known as “Big Pharma.”

That Big Pharma took over and monopolized American medicine, promoting their own patented, profit-making products and suppressing all others, isn’t even a conspiracy theory.

In fact, it was recorded for all to see in 1953 …

 

The Fitzgerald Report

In the early 1950s, US Senator Charles Toby enlisted an investigator with the Interstate Commerce Commission named Benedict Fitzgerald to examine allegations of conspiracy and monopoly in medicine. Toby had become interested in the issue after his own son had gotten cancer and been given less than two years to live by orthodox medicine before pursuing alternative treatments and being cured.

The resulting 1953 report, known as the Fitzgerald Report, was truly shocking. It concluded that Big Pharma had been involved in “a conspiracy of alarming proportions.”

First, there was

“The organized effort to hinder, suppress and restrict the free flow of drugs which allegedly proven successful in cases where clinical records, case history, pathological reports, and x-ray photographic proof, together with the alleged cured patients, are available.”

On top of that,

“Public and private funds have been thrown around like confetti at a country fair to close up and destroy clinics, hospitals, and research laboratories which do not conform to the viewpoint of medical associations.”

The report even noted that Big Pharma had conspired to suppress at least 12 promising cancer treatments, including mentioning Hoxsey Therapy by name.

It was an unfathomably damning report, making clear that the tentacles of a Big Pharma conspiracy to suppress alternative medicine were everywhere.

But as it turns out, the report did not go far enough

 

The Suppression of Laetril as a Cure for Cancer

Oftentimes when a new natural cancer treatment appears, the assertion from the medical establishment is that the new treatment is either unproven, or disproven. There is no better example of what this really means in the era of Big Pharma than the case of a cancer treatment called Laetrile.

In 1952, a year before the Fitzgerald Report, a biochemist named Ernst Krebs proposed that cancer was a deficiency disease which could be cured with a compound called amygdalin, found in over 1,200 plants, and most specifically in the seeds of apricots. By extracting this amygdalin from apricot kernels, Krebs created a product he called Laetrile.

Over the course of many years, Krebs conducted numerous lab experiments on animals which showed that Laetrile was an effective cancer treatment, that somehow, it caused cancer cells to self-destruct.

By the 1960s, a doctor named John Richardson had picked up the research, and had even begun treating human patients with Laetrile. Unsurprisingly, the Rockefeller-controlled FDA launched a massive media campaign against Richardson and Laetrile, claiming that the treatment was toxic and dangerous. By 1971, the FDA officially banned Laetrile, and, in 1972, they stormed Richardson’s clinic and arrested him.

But even after Richardson was jailed, people kept asking about Laetrile, writing to government officials, medical journals, and scientific labs demanding answers. At this point, Big Pharma knew they had to put their foot down once and for all. They needed to undertake official testing which proved that Laetrile didn’t work.

The testing would take place at Memorial Sloan-Kettering Cancer Center in New York City, and what would happen next would come to be described as “one of the biggest medical cover-ups the world of cancer research has ever seen.”

The tests would be led and directed by Dr. Kanematsu Sugiura, known at that time as “the preeminent cancer researcher in America.” He had over 60 years of experience, publishing hundreds of academic papers on the subject. As one scientist said, “When Dr. Sugiura publishes, we know we don’t have to repeat the study, for we would obtain the same results he has reported.”

In 1972, testing began, with Laetrile being administered to mice with many different types of cancerous tumors. At its completion, Dr. Sugiura concluded that Laetrile stopped the spread of cancer, inhibited the growth of tumors, and acted as a cancer prevention. It even provided relief from pain and improved general health.

This seemed to be incredible news. Except, there were three Rockefellers sitting on the board of Sloan-Kettering, as well as a dozen more people representing companies making big money from Big Pharma. When they caught word of the test results, “all hell broke loose,” and another round of tests was ordered.

Unfortunately for Sloan-Kettering executives, the second round of testing only confirmed the first. Except this time, with two confirmed tests from the legendary Dr. Sugiura in the books, mainstream media was forced to cover it. Had a cure for cancer really been found, they asked?

Sloan-Kettering officials refused to speak with the media, refused to discuss the results or answer any questions, saying only in a prewritten statement that a third round of tests had been ordered in order to “clarify” the results, as if they had not been twice clarified already.

In this third test, a new wrinkle would be introduced – Dr. Sugiura would be blinded. He would not know which half of the mice would be receiving Laetrile, and which half would be given a saline solution, as if this eminently respected scientist was going to somehow manipulate the results.

After four weeks, Dr. Sugiura could see which of the mice were being given Laetrile, since mice in some of the cages had fewer and smaller tumors, while mice in the other cages showed no effects. Sloan-Kettering overseers who were supervising the project confirmed to Dr. Sugiura that he was correct. For a third time, Laetrile’s cancer treating properties were confirmed.

Except, arguing that Dr. Sugiura was no longer blinded since he knew which cages were which, Sloan-Kettering officials shut the tests down.

They would try yet again to get the results they were looking for with a fourth test. This time, not only would Dr. Sugiura be blinded, but the mice who were receiving the treatment would be mixed together with those who weren’t. Dr. Sugiura warned that this was dangerous because there was no dependable way to ensure the lab techs administering the treatment would be able to identify the correct mice every time. And, in fact, this is exactly what happened. Some of the mice who were purportedly only being given a saline solution saw their tumors stop growing.

“There’s something funny here,” Dr. Sugiura professed. The ‘something funny’ was that the treatments had been mixed, with many mice receiving some Laetrile and some saline solution, just as Dr. Sugiura had predicted.

Yet, in this case, the legitimacy of the results wasn’t important to Sloan-Kettering’s Rockefeller board. Immediately, they announced that “results from the experiment do not confirm the earlier positive findings of Sugiura.”

Then, they called a press conference attended by most of mainstream media and declared, “Laetrile was found to possess neither preventive, nor tumor-regressant, nor anti metestatic, nor curative anti-cancer activity” – the exact opposite of what the first three tests had shown.

At the end of the press conference, the floor was opened to questions from the media, which is when things took a dramatic turn.

“Dr. Sugiura,” someone shouted, “Do you stick by your belief that Laetrile stops the spread of cancer?”

The room fell silent as the fabled Dr. Sugiura rose to his feet and replied, “I stick.”

The next month, Sloan-Kettering executives appeared before a Senate subcommittee hearing to decide the fate of Laetrile. While it had been banned by the FDA in 1971, some states were challenging this decision.

At the hearing, Sloan-Kettering executives asserted, “There is not a particle of scientific evidence to suggest that Laetrile possesses any anti-cancer properties at all” totally ignoring the three full lab tests of scientific evidence from “the preeminent cancer researcher in America.” As a result of the testimony, Laetrile was officially banned nationwide by 1980.

Afterwards, Dr. Sugiura was asked why Sloan-Kettering was so against Laetrile. “I don’t know,” he replied, “Maybe the medical profession doesn’t like it because they are making too much money.”

When Big Pharma says an alternative treatment has been disproven, this is what they mean.

 

Is Big Pharma Suppressing Information for Profit?

But what about if tests were not done in a Rockefeller-controlled lab. What if one were to do their own tests, build their own case studies, and present them to the appropriate authorities themselves?

One man provided an answer.

Stanislaw Burzynski was a Doctor of Biochemistry who immigrated to the US from Poland in 1970, where he took up a position as a researcher and assistant professor at Baylor University in Houston, Texas. There, he discovered something which he called antineoplastons – naturally occurring “molecular switches” in the human body which, Burzynski asserted, the body used to control cancer growth.

At first, Burzynski’s discoveries were well received by colleagues. In fact, so impressive was his work that he was offered a tenured position in Baylor’s Department of Pharmacology. He should have been thrilled, yet Burzynski knew that if he accepted, he would lose his independence as a researcher. So, he refused the position, instead choosing to found the Burzynski Research Institute in order to continue his work. On his way out the door at Baylor, his boss warned him, “Just wait, Burzynski. They’re going to kick your ass.”

In short order, Burzynski and his clinic were investigated by local medical authorities for using “unapproved medications,” while the Rockefeller-founded American Cancer Society put antineoplastons on its “unproven methods” list, and those who had been funding his research pulled their support.

In 1983, the FDA filed a lawsuit to get him to shut down his operation, and when this failed, FDA agents and federal marshals simply raided the Burzynski Research Institute and seized over 200,000 confidential documents.

Still Burzynski continued on. He raised millions of dollars through his Institute to pay for clinical trials for antineoplastons, money Big Pharma companies are more than happy to spend since they know they will recoup it when their products are patented. By the mid-90s, he was able to provide the FDA with sixty clinical trials, meeting the requirement for their Phase I testing.

For another decade he worked, compiling hundreds more clinical trials, meeting the requirements for Phase II of testing on his own at the cost of millions of dollars.

In 2011, Burzynski began Phase III testing, which involves thousands of participants and can last for years, again, at the cost of many millions of dollars. He was closing in on the finish line by 2013, which is when the FDA stepped in and put a stop to the trials. Their reason? They complained that the Burzynski Research Institute was doing all of the testing, when, of course, this is simply how the FDA approval process works. The only difference is usually the testing is being done by a Big Pharma company.

Finally, in 2017, the FDA cancelled antineoplaston clinical trials for good, refusing Burzynski the right to even conduct the tests. Moreover, Burzynski had his medical license revoked and was fined hundreds of thousands of dollars for his trouble.

The point made by Burzynski and his antineoplastons, by Sloan-Kettering’s Laetrile trials, is simple. It’s a case of ‘you’re damned if you do and damned if you don’t.’ If testing is conducted in a Rockefeller Big Pharma laboratory, it will be repeated and repeated and repeated until it gives the desired results, no matter how manipulated these results might be. And if you conduct the tests yourself, spending millions upon millions of dollars, the results will still not be accepted.

03-04-burzynski-02.webp?w=600&q=75&f=aa0b9051be2d61eaa37d43d89e96624f
Over 60 patients defended Dr. Burzynski stating they were cured by him.

Big Pharma controls the testing, they control approval, they control academic thought. But look closer, and it goes even further than that.

Big Pharma employs 1,270 registered lobbyists in the halls of government, more than two Big Pharma lobbyists for every member of congress, at a cost of over $200 million per year. They also spend tens of millions of dollars every year financing political campaigns – nearly every member of congress is funded by Big Pharma. On top of that, Big Pharma lobbyists and executives are repeatedly put in charge of the government bodies tasked with overseeing the pharmaceutical industry, like the FDA. Simply, the production and sale of medicine is tightly regulated by government, and Big Pharma controls the government.

Is it really so hard to believe that Big Pharma would use its control of academia, science, and government, to suppress valuable information for their own profit?

In reality, suppressing truth for profit is as American as apple pie – from the 1950s, when tobacco companies fought to suppress lung cancer knowledge as people died, to modern times, when oil companies insist that the debate around climate change is still ongoing, even as the consequences scientists promised decades ago are all around.

But pharmaceutical companies? Those purportedly tasked with providing health? Would they really suppress a cure for cancer? And kill people?

Actually, that Big Pharma would knowingly and intentionally kill people for profit is not conspiracy, it is established fact, admitted on record in American courts.

 

How Big Pharma Created the American Opioid Crisis

In October of 2020, Big Pharma flagbearer Purdue Pharma pled guilty in court to criminal charges for its role in the American opioid crisis, agreeing to pay some $8.3 billion in the settlement.

Opioids were a new type of synthetic pain medication that emerged in the early-1990s, which Big Pharma companies like Purdue aggressively promoted while suppressing information about the dangers, most specifically, the extreme addictiveness. Today, not only is chronic pain more prevalent than ever in the US, but nearly a million people have died from opioid overdoses, and another 3 million have fallen victim to addiction.

In pleading guilty at trial, Purdue Pharma admitted on record to having supplied drugs “without legitimate medical purpose.” In other words, the purpose of opioids wasn’t medical, it wasn’t to cure pain; it was to get people addicted so they’d buy more. Purdue even admitted to paying off health insurance companies to deny coverage for alternative care, forcing people to take opioids, and paying off doctors to overprescribe their product to patients.

depositphotos_178773006-stock-photo-macro-of-oxycodone-opioid-tablets.jpg

By February of 2022, four more of the largest Big Pharma companies had reached a $26 billion settlement for their own role in the crisis. These, along with Purdue, are the largest and most powerful pharmaceutical companies in the country, the ones who lobby governments and sit on medical boards. And here they are, on the record, poisoning people for profit.

 

Chemotherapy - The Only Legal "Cure" for Cancer

Apply this knowledge to cancer specifically, and think about what chemotherapy is.

The treatment was first conceptualized by doctors examining soldiers who had been exposed to mustard gas during World War II. Noticing that mustard gas had toxic effects on the blood cells of soldiers, doctors surmised that it could be used against cancer cells.

This was how the first version of chemotherapy, and model for all subsequent versions, was created, from a compound used as an agent of chemical warfare. This is what Big Pharma is telling cancer patients to put in their body.

Of course, it is no big secret that chemotherapy is toxic. Cancer patients are warned that side effects can include everything from vomiting and nausea, to infertility, to organ damage, and even death. They are even warned it can lead to a “second cancer.” In other words, patients are told chemotherapy might treat their cancer, but that it might also cause cancer; it might save their life, but it might also kill them. As one former president of the American Chemical Society succinctly put it, “chemotherapy does much, much more harm than good.”

A bit like opioids …

But that’s the point; there are no profits in the cure. Big Pharma needs people sick, so that people need more and more expensive “treatment.”

In this, the era of Big Pharma is alone in the history of medicine …

Link

The Dinarian On Locals is a labor of love that I pour my heart and soul into during my personal time. Countless hours are dedicated to delivering you the most up-to-date, unfiltered, and authentic news and information. Your support means the world to me, and I invite you to consider making a donation or becoming a dedicated supporter of this project. Any amount of XRP donations can be sent by scanning the QR code below and are greatly appreciated. ~ Namaste🙏🏼The Dinarian

 

 

community logo
Join the TheDinarian Community
To read more articles like this, sign up and join my community today
1
What else you may like…
Videos
Podcasts
Posts
Articles
Lady asks Ai - why are they really blocking out The Sun?

Finally an AI that tells it like it is..
I wish I knew which LLM this was.
If you know, please let me know in the comments.

00:02:53
🇺🇸 Elon Musk says he's "disappointed" to see the US Government's new massive spending bill.

"This increases the budget deficit and undermines the work the DOGE team is doing."

00:00:31
JUST IN: 🇺🇸 Secretary of Commerce Howard Lutnick says "tariffs are not going away."

Commerce Secretary Howard Lutnick has stated that the 10% baseline tariff on imports will likely remain in place for the foreseeable future, according to his comments on CNN's "State of the Union" on May 11, 2025.

Lutnick insists that the tariffs are not going away and that businesses and foreign countries, rather than consumers, will bear the cost of the tariffs.

Additionally, Lutnick has maintained that the baseline 10% tariff on all countries will not be reduced below this rate.

He has also emphasized that the tariffs are a necessary step to reset global trade dynamics and open up new markets for American exporters.

Despite these assurances, economists and consumer sentiment surveys generally disagree with Lutnick's stance, suggesting that consumers are likely to face increased costs due to the tariffs.

00:00:17
👉 Coinbase just launched an AI agent for Crypto Trading

Custom AI assistants that print money in your sleep? 🔜

The future of Crypto x AI is about to go crazy.

👉 Here’s what you need to know:

💠 'Based Agent' enables creation of custom AI agents
💠 Users set up personalized agents in < 3 minutes
💠 Equipped w/ crypto wallet and on-chain functions
💠 Capable of completing trades, swaps, and staking
💠 Integrates with Coinbase’s SDK, OpenAI, & Replit

👉 What this means for the future of Crypto:

1. Open Access: Democratized access to advanced trading
2. Automated Txns: Complex trades + streamlined on-chain activity
3. AI Dominance: Est ~80% of crypto 👉txns done by AI agents by 2025

🚨 I personally wouldn't bet against Brian Armstrong and Jesse Pollak.

👉 Coinbase just launched an AI agent for Crypto Trading
Ripple Strikes Major Deal: Germany’s DZ BANK Goes Live with XRP Custody

Ripple just made a massive move in Europe, quietly. According to crypto analyst pumpius on X, Germany’s second-largest bank, DZ BANK, has officially gone live with a Ripple-powered digital asset custody platform.

With over €350 billion in assets under custody, this partnership marks a huge milestone for Ripple, especially as it slips into the core infrastructure of traditional finance without making a huge hype.

https://coinmarketcap.com/community/articles/683ec9ef51bc2514939244d6/

Legal Expert Refutes Claims Against XRP’s Legal Status

What to Know:

🔹️Ripple’s lawyer disputes claims on XRP’s legal clarity and market impact.

🔹️Ripple vs. SEC lawsuit continues over unresolved settlement issues.

🔹️XRP’s judicial status differs from Bitcoin’s regulatory perception.

https://bitcoininfonews.com/xrp-legal-status-clarity-debate/

BREAKING VERITASEUM NEWS 🚀

BREAKING: Court docs show SEC attorneys told federal judge account was 'personal' to get asset freeze in Veritaseum case. Their own filing same day showed it was corporate account. Now $9.5M settlement being challenged as #FraudUponTheCourt.

https://x.com/SovereignRiz/status/1929679624323145819?s=19

post photo preview
Fund Tokenization Prepares Asset Managers for ‘Perfect Storm’

Synopsis:

  • Great Wealth Transfer will see $84 trillion of intragenerational asset transfer over the next 20 years
  • Gen Y and Z investors favor investment in alternative asset types, which tokenization makes more investable for HNW clients
  • Tokenization encourages platform changes, and will ultimately bring additional operational benefits

A triumvirate of large-scale market changes are set to transform the asset management industry over the next decade.

With trillions of dollars worth of assets set to flow into the wallets of Gen X, Y, and Z investors, much of which will accumulate onchain, asset managers who move first to serve this new market will gain an advantage in capturing this revenue opportunity. The immediate opportunity is similar to when the ETF format was introduced in 1993, with first-mover State Street launching the SPY (SPDR S&P 500 ETF)—now one of the largest ETFs globally. The tokenized asset format is today’s generational opportunity.

Tokenization can unlock accessibility to alternative asset types and more composable assets and structures, enabling a significant change in how investors manage portfolios. With greater automation and rules-based investment allocations, entirely new strategies could also become economically viable. Integrating existing platforms with next-generation digital systems will enable the industry to modernize in stages, ultimately allowing for the adoption of new asset types at scale.

The forthcoming vicennial transformation of the industry will enable it to transform and emerge triumphant. Those at the forefront of this technology evolution stand to dominate and shape the future of asset management.

 

Great Wealth Transfer prompts global investment shake-up

The asset management industry is on the cusp of the largest wealth transfer event ever, set to last for the next two decades. Consulting firm Cerulli Associates estimates $84 trillion in assets is set to change hands as wealth passes from the baby boomer generation to Gen X, Y, and Z investors.

However, the investment behavior of these younger benefactors differs significantly from their forebears in two ways. Holding Web3 wallets and accounts on Robinhood, rather than brokerage accounts like their parents, millennials are opting for a more self-service model in their long-term holdings. Add to that the shift in risk appetite, searching for higher growth through less conventional asset types like private markets and crypto, and the need for the industry to transform quickly is clear.

Whilst the industry is not currently set up to offer this new investor class more customization, as opposed to one-size-fits-all product offerings, an 80% majority of asset managers believe customization for the masses will be an important investment strategy in the next five years.

 
 

                                          Ryan Lovell, Chainlink Labs

 

While asset managers could build their own proprietary blockchain infrastructure and smart contract systems from the ground up, that approach would require significant resources and specialized engineers, extend time to market, and be at higher risk of technical vulnerabilities or implementation errors. On the other hand, fully outsourcing the implementation would leave them with limited roadmap control, interoperability, and customizability, along with dependency risks.

Ryan Lovell, director of capital markets at Chainlink Labs, commented: “That’s why leading asset managers are taking a hybrid approach, leveraging both existing systems and Chainlink’s decentralized infrastructure to implement modular solutions that can scale across multiple blockchains.”

 

Industry transformation through tokenization

The launch of tokenized funds by firms such as BlackRock, Franklin Templeton, and Fidelity International has created a need for the fund administration industry to evolve to an onchain format. However, nearly all, 93% of fund services firms, have not automated data inputs, data checks, and key workflows, so their operations are still manually intensive, leading to increased operational costs, reduced liquidity, and missed investment opportunities. Standard transfer agent processing can take between one and three days for routine transactions, and between five and seven days for complex cases requiring additional compliance checks, cross-border settlements, or manual document verification.

“Operational efficiency is just the starting point of tokenizing funds,” said Lovell. “The real value is meeting the needs of future investors who are increasingly accumulating wealth across multiple blockchain networks.”

In order to reach this new onchain world, asset managers and their service providers may not want to make a huge investment to completely change their infrastructure, but instead adapt their existing systems to make them compatible with multiple blockchains.

For example, in November 2024, SBI Digital Markets, UBS Asset Management, and Chainlink completed the implementation of a tokenized fund to demonstrate how existing fund administration processes can be successfully made compatible with tokenized funds.

SBI Digital Markets, as a custodian and fund distributor, used smart contracts, oracle networks, and multiple blockchains to automate its processes. One of the key components was the digital transfer agent smart contract, which used multiple oracle networks from Chainlink and its blockchain-agnostic architecture to create a unified golden record.

Lovell compared the digital transfer agent to an offchain/onchain coordinator that does everything that a traditional transfer agent does, but in digital form.

“It does not replace the existing system but enables firms to be compatible with blockchain and then offer a service that can scale to all their customers,” he said. “Asset managers should be demanding this from their service providers.”

The pilot showed that a tokenized fund could maintain its share register on one blockchain while using Chainlink’s Cross-Chain Interoperability Protocol (CCIP) to enable the processing of intensive fund lifecycle activities such as subscriptions and redemptions on different blockchains while meeting institutional security and compliance standards.

Swift, UBS Asset Management, and Chainlink also settled tokenized fund subscriptions and redemptions using the Swift network, which enables payments with fiat currencies across more than 11,500 financial institutions in over 200 countries.

                                     Winston Quek, SBI Digital Markets

Winston Quek, CEO at SBI Digital Markets, said in a statement: “This new way of launching fund structures and administering them via smart contracts empowers both fund managers and their service providers to deliver new onchain financial products and lower operational costs to investors, both things they are actively looking for.”

In addition to lowering costs, using blockchains increases transparency and allows real-time reconciliation between the fund distributor and the fund issuer. Lovell highlighted that Chainlink can also use the same architecture to enable investors who want to hold tokens that are backed by offchain assets, settle these tokens across any blockchain, incorporate data that is needed to process transactions onchain, such as NAV data, and coordinate payments between distributors and the asset managers.

In the U.S. there are requirements around private and public funds and Chainlink enables asset managers to consolidate and consume onchain record keeping while fulfilling regulatory obligations. U.S. funds also require the distributor to onboard users and buy and sell the fund while the custodian and fund accountant provide reporting data.

“We allow all of those service providers to coordinate outside of their firewalls,” said Lovell. “Chainlink’s goal is to enable the TradFi and DeFi worlds to seamlessly connect, which increases utility.”

 

The Great Wealth Transfer is driving asset management onchain

With $84 trillion set to flow from baby boomers to Gen X, Y, and Z, their demand for alternative asset types and customization will shape the future of asset management. While today’s systems may be prohibitively expensive to offer these benefits at scale, tokenization changes the economics.

Tokenized funds by BlackRock, Franklin Templeton, and Fidelity International have already proven the demand for onchain assets, while a solution by SBI Digital Markets, UBS Asset Management, and Chainlink has demonstrated the operational efficiencies of blockchain technology and how onchain assets can be provided at scale.

The choice is clear for asset managers and service providers: embrace the tokenization revolution and lead the next era of finance or risk being left behind. Those who act now will not only gain a first-mover advantage but also shape the future of the industry.

Source

🙏 Donations Accepted 🙏

If you find value in my content, consider showing your support via:

💳 PayPal: 
1) Simply scan the QR code below 📲
2) https://www.paypal.me/thedinarian

🔗 Crypto – Support via Coinbase Wallet to: [email protected]

Or Buy me a coffee: https://buymeacoffee.com/thedinarian

Your generosity keeps this mission alive, for all! Namasté 🙏 The Dinarian

Read full Article
post photo preview
Stellar's Ecosystem Surges Forward: Smart Contracts, Lightning Speed, and Real-World Impact in 2025

The Stellar blockchain ecosystem is experiencing remarkable momentum in 2025, with groundbreaking technical achievements and expanding real-world adoption that position it as a major player in the decentralized finance landscape. From lightning-fast transaction speeds to innovative smart contract capabilities, Stellar is demonstrating that blockchain technology can deliver both performance and practical utility.

Technical Breakthroughs Drive Performance

The Stellar Development Foundation's Q1 2025 quarterly report reveals impressive technical milestones that showcase the network's maturation. The platform now processes an astounding 5,000 transactions per second with remarkably fast 2.5-second block times, putting it among the fastest blockchain networks in operation today.

This performance leap isn't just about raw numbers—it represents Stellar's commitment to creating infrastructure that can handle real-world demand. Whether it's cross-border payments, asset tokenization, or decentralized applications, the network's enhanced capabilities provide the foundation for scalable blockchain solutions.

Smart Contracts Get Smarter with Soroban

One of the most significant developments has been the launch and continued evolution of Soroban, Stellar's smart contract platform. The introduction of Contract Copilot represents a major advancement in developer experience, enabling faster and safer smart contract development through enhanced tooling and guidance.

This focus on developer experience is crucial for ecosystem growth. By lowering barriers to entry and improving the development process, Stellar is positioning itself to attract innovative projects and talented developers who might otherwise choose competing platforms.

New Token Standards Meet Market Needs

The Stellar Development Foundation has introduced new token standards developed specifically based on feedback from developers and institutional users. This responsive approach to platform development demonstrates Stellar's commitment to building technology that meets actual market needs rather than theoretical requirements.

These standards are particularly important as institutional adoption continues to grow, with organizations requiring robust, compliant, and flexible token frameworks for their blockchain initiatives.

Global USDC Integration Expands Utility

The integration of USDC across Stellar's global network represents a significant milestone for practical cryptocurrency adoption. Stablecoins like USDC provide the price stability necessary for everyday transactions and business operations, making them crucial for blockchain platforms seeking real-world utility.

This integration is particularly impactful in emerging markets, where access to stable digital currencies can provide financial services to underbanked populations and facilitate more efficient cross-border transactions.

Industry Events Build Community Momentum

The Stellar ecosystem's growing influence is evident in its presence at major industry events. The foundation's participation as a sponsor at Consensus 2025 in Toronto and Digital Assets Week in New York demonstrates its commitment to engaging with builders, investors, and institutional leaders across the blockchain space.

These events serve as crucial networking opportunities and platforms for showcasing innovative projects within the Stellar ecosystem. Recent Meridian events have highlighted creative projects like Skyhitz and HoneyCoin, illustrating the collaborative spirit and diverse applications being built on the platform.

Real-World Impact in Emerging Markets

Perhaps most importantly, Stellar's growth isn't just about technical metrics—it's about real-world impact. The platform's focus on emerging markets addresses genuine financial inclusion challenges, providing efficient payment rails and access to digital financial services where traditional banking infrastructure may be limited.

This practical approach to blockchain implementation sets Stellar apart from projects that focus primarily on speculative trading or theoretical use cases. By solving actual problems for real users, Stellar is building sustainable demand for its technology.

Looking Ahead: Enterprise-Grade Infrastructure

Stellar positions itself as offering enterprise-grade asset tokenization alongside its DeFi capabilities and payment infrastructure. This comprehensive approach makes it attractive to institutions looking for a single platform that can handle multiple blockchain use cases.

The combination of fast transactions, low costs, smart contract capabilities, and regulatory-conscious development creates a compelling value proposition for enterprises considering blockchain adoption.

The Road Forward

As 2025 progresses, Stellar's ecosystem appears well-positioned for continued growth. The technical infrastructure improvements, developer-focused enhancements, and real-world adoption initiatives create a strong foundation for expanding use cases and user adoption.

The blockchain industry has seen many projects promise revolutionary capabilities, but Stellar's focus on delivering measurable performance improvements and practical solutions suggests a mature approach to blockchain development. With transaction speeds that rival traditional payment systems and growing institutional adoption, Stellar is demonstrating that blockchain technology can move beyond experimental phases into mainstream utility.

For developers, institutions, and users looking for blockchain solutions that prioritize both performance and practical applicability, Stellar's 2025 developments represent significant progress toward a more accessible and useful decentralized financial ecosystem.

Source: The Dinarian ⚡ Claude AI

🙏 Donations Accepted 🙏

If you find value in my content, consider showing your support via:

💳 PayPal: 
1) Simply scan the QR code below 📲
2) https://www.paypal.me/thedinarian

🔗 Crypto – Support via Coinbase Wallet to: [email protected]

Or Buy me a coffee: https://buymeacoffee.com/thedinarian

Your generosity keeps this mission alive, for all! Namasté 🙏 The Dinarian

Read full Article
post photo preview
Soroban Security Audit Bank: Raising the Standard for Smart Contract Security

The Stellar Development Foundation (SDF) is deeply committed to helping ensure that the highest security standards are available for projects building on the Stellar network. Last year SDF launched the Soroban Security Audit Bank, an initiative to provide projects access to auditing experts and tooling that are proven to help prevent hacks by catching potential bugs, inefficiencies, and security flaws before contracts go live. Through the Soroban Security Audit Bank, we’re empowering teams building on Soroban with comprehensive security audits from leading audit firms, enhanced readiness support, and robust tooling, significantly elevating the ecosystem’s safety and efficiency.

Since launch, the Soroban Security Audit Bank has successfully conducted over 40 essential audits, deploying over $3 million to support security of the smart contracts on Stellar. Check it out!

 

Ecosystem Success Stories: How the Soroban Audit Bank Drives Security Forward

By making automated formal verification available to developers, in addition to allocating significant budget for securing many of the top DeFi protocols built on top of Stellar, SDF has established a new security standard in the Web3 ecosystem. Mooly Sagiv, Co-Founder of Certora
SDF has been a strong partner as we’ve worked with teams across the Stellar ecosystem. SDF’s Audit Bank initiative allows for a smooth and streamlined review process, and is a clear reflection of the Stellar ecosystem’s enhanced commitment to security. Robert Chen, CEO of OtterSec
 

Leading projects within the Soroban ecosystem have highlighted the impact of the Audit Bank

Finding a good auditor is difficult, expensive, and high-stakes. The Audit Bank streamlines the process and supports ecosystem projects with security review at critical growth milestones. Markus Paulson, Co-Founder of Script3
The audit firms we worked with deeply understood the full ecosystem and the underlying protocols used. Their expertise and the tools from the Audit Bank strengthened our security and supported user and investor trust. Esteban Iglesias Manríquez, Co-Founder of Palta.Labs

What's New in 2025: Enhanced Audit Support for Soroban Builders

Teams building financial protocols, high-dependency data services, high-traction dApps funded by the Stellar Community Fund are able to request an audit and will typically be matched with a reputable audit firm within two weeks. We recently restructured the program for this year to enhance audit efficiency and incentivize accountability, and rapid and complete vulnerability remediation:

  • Complimentary Initial Audit: Projects will need to contribute 5% of the audit cost upfront, but this co-payment amount is eligible for a full refund, provided that critical, high, and medium vulnerabilities identified are swiftly remediated within 20 business days of receiving the initial audit report (learn more).
  • Incentivized Security at Key Traction Milestones: Complimentary, extensive follow-up audits are available as projects achieve critical traction milestones (e.g., $10M and $100M TVL). These audits include deeper assessments such as formal verification or competitive audits, significantly boosting project security at pivotal stages.
  • Advanced Security Tooling: Projects can enhance their security self-serve through complimentary or discounted access to specialized tooling, which provide vulnerability detection and formal verification capabilities (see full list of available tooling). These tools are encouraged to capture ‘easy-to-spot’ issues prior to audit as well as a final check post-audit to increase the effectiveness and thoroughness of audits.
  • Enhanced Audit Readiness Support: Projects receive structured preparation support, including the implementation of best practices and security standards based on the STRIDE threat modeling framework. This ensures project teams are thoroughly prepared, optimizing audit efficiency and minimizing delays.

Get Started Today

If you're already funded through the Stellar Community Fund, meet the criteria and ready to secure your smart contracts, check your email for an invitation to submit an audit request–if you haven’t received one, contact [email protected].

If you haven't built on Stellar yet, we encourage you to start your journey with the Stellar Community Fund to become eligible for future security audits and ecosystem support. For any broader questions on the program, contact [email protected].

Also, we’re organizing an exciting series of workshops–join us for the kick-off on Soroban Security Best Practices on Friday, May 30, 2025 at 2 PM ET on @StellarOrg. Together, we're shaping a secure and resilient future for smart contracts on Stellar.

Source

🙏 Donations Accepted 🙏

If you find value in my content, consider showing your support via:

💳 PayPal: 
1) Simply scan the QR code below 📲
2) https://www.paypal.me/thedinarian

🔗 Crypto – Support via Coinbase Wallet to: [email protected]

Or Buy me a coffee: https://buymeacoffee.com/thedinarian

Your generosity keeps this mission alive, for all! Namasté 🙏 The Dinarian

Read full Article
See More
Available on mobile and TV devices
google store google store app store app store
google store google store app tv store app tv store amazon store amazon store roku store roku store
Powered by Locals